Mestranol/hydroxyprogesterone acetate

Mestranol /
hydroxyprogesterone acetate
Mestranol (top) and
hydroxyprogesterone acetate (bottom)
Combination of
MestranolEstrogen
Hydroxyprogesterone acetateProgestogen
Clinical data
Trade namesHormolidin
Other namesME/OHPA; EEME/OHPA
Routes of
administration		By mouth
Drug classEstrogen; Progestogen

Mestranol/hydroxyprogesterone acetate (ME/OHPA), sold under the brand name Hormolidin, is a combination medication of mestranol (ME), an estrogen, and hydroxyprogesterone acetate (OHPA), a progestin, which was reportedly used as a sequential combined birth control pill for women in the early 1970s.[1] It was formulated as oral tablets and contained 16 tablets of 80 μg ME, 5 tablets of 80 μg ME and 100 mg OHPA, and 7 placebo tablets (28 tablets in total).[1] The medication was manufactured by the pharmaceutical company Gador in Argentina.[1]

See also

References

  1. ^ a b c Rudel HW, Kinel FA (September 1972). "Oral Contraceptives. Human Fertility Studies and Side Effects". In Tausk M (ed.). Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents. Vol. II. Pergamon Press. pp. 385–469. ISBN 978-0080168128. OCLC 278011135.



This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.